Combination bevacizumab plus temsirolimus for second-line treatment of metastatic kidney cancer

A recent phase 2 study evaluated the combination of bevacizumab with temsirolimus in 39 patients with metastatic renal cell carcinoma (mRCC) after failure of first-line treatment with a vascular endothelial growth factor (VEGF) receptor inhibitor. After 6 months, 50.9% of patients were progression-free and median time to progression of the disease was 6.8 months. The […]

read more

Safety and tolerability of atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer

The combined safety results of two studies with the atezolizumab plus bevacizumab combination were presented at the European Society of Medical Oncology (ESMO) Congress in Munich, Germany last week. The phase 2 IMmotion 150 clinical trial compared the efficacy of the atezolizumab plus bevacizumab combination with atezolizumab alone and sunitinib alone, and then allowed for crossover to […]

read more

Potential biomarkers may predict response to TKIs in metastatic kidney cancer

A recent study published in Clinical Cancer Research and conducted in France has identified potential biological markers that are related to the formation of new blood vessels (angiogenesis) and regulated by the levels of oxygen reaching the tissues (hypoxia). These biomarkers have been found to be strong predictors of response, progression-free survival (PFS), and overall survival […]

read more

Patient-reported outcomes for atezolizumab plus bevacizumab combination

Patient-reported outcomes from the phase 3 IMmotion151 study, which assessed the atezolizumab plus bevacizumab combination versus sunitinib in metastatic renal cell carcinoma (RCC) patients, were presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this week. In the IMmotion151 clinical trial, the combination of atezolizumab plus bevacizumab improved progression-free survival […]

read more

Combination therapies for kidney cancer

The following is a Practice Update interview with Dr Hans Hammers, Associate Professor, Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas. During this interview, Dr Hammers talks about the upcoming combination therapies for the treatment of metastatic renal cell carcinoma (mRCC), such as nivolumab/ipilimumab, axitinib/pembrolizumab, cabozantinib/nivolumab, tivozanib/nivolumab and bevacizumab/atezolizumab combinations currently in development. The clinical trials […]

read more

Atezolizumab plus bevacizumab combination is positive for untreated metastatic kidney cancer

The combination of immunotherapy atezolizumab (Tecentriq) with targeted therapy bevacizumab (Avastin) has been shown to delay the growth of metastatic renal cell carcinoma (mRCC) in a phase III clinical trial called IMmotion151. In the trial, the combination delayed cancer growth by about 3 months compared to standard treatment with sunitinib, another targeted therapy. The benefit […]

read more

Positive interim results for atezolizumab plus bevacizumab combination in advanced RCC

Interim results from the phase III IMmotion151 study to assess a combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) for advanced or metastatic renal cell carcinoma (RCC) have been reported to have improved progression-free survival (PFS), compared to sunitinib (Sutent) as a first-line treatment. The researchers said that the combination provided a statistically significant and clinically […]

read more

Results from the IMmotion 150 clinical trial comparing atezolizumab with sunitinib

In this interview, Dr Daniel George from the Duke Cancer Institute, Durham, USA discusses results from the IMmotion 150 clinical trial. IMmotion 150 was a randomised phase II study comparing sunitinib with atezolizumab, a PD-L1 inhibitor, versus the combination of atezolizumab with bevacizumab, a VEGF-targeted antibody, as a first-line treatment for previously untreated renal cell carcinoma patients. The […]

read more

Combination treatment with atezolizumab plus bevacizumab improves progression-free survival

Results from the IMmotion150 phase II clinical trial showed that a combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) improved progression-free survival (PFS) in patients with untreated metastatic renal cell carcinoma (mRCC) compared with standard treatment with sunitinib (Sutent). These results were presented at the 2017 European Society of Medical Oncology (ESMO) conference in Madrid, Spain […]

read more

Type of long-term response to targeted therapy affects outcomes for advanced kidney cancer

A retrospective study conducted by researchers in the Czech Republic has analysed the outcomes of 219 people with metastatic renal cell carcinoma (mRCC) who received first-line treatment with vascular endothelial growth factor (VEGF) inhibitors, for example sunitinib, sorafenib, pazopanib, or bevacizumab, for at least 2 years. The vast majority of patients (166 patients, 75.8%) received […]

read more
Showing 11 to 20 of 27 results
  TOP